{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:50:47Z","timestamp":1781376647634,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ministry of Health"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.msard.2020.102005","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T06:14:22Z","timestamp":1581488062000},"page":"102005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood\u2013brain barrier breakdown and peripheral plasmablasts"],"prefix":"10.1016","volume":"41","author":[{"given":"Satoru","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baku","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Izaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1231-1933","authenticated-orcid":false,"given":"Satoru","family":"Oji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikoaki","family":"Fukaura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102005_bib0001","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B Lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol. Neuroimmnunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102005_bib0002","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-Encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2020.102005_bib0003","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00415-005-0817-9","article-title":"Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases","volume":"252","author":"Brettschneider","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102005_bib0004","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti- aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.msard.2020.102005_bib0005","doi-asserted-by":"crossref","first-page":"e83036","DOI":"10.1371\/journal.pone.0083036","article-title":"Plasmablasts as migratory IGG-producing cells in the pathogenesis of neuromyelitis optica","volume":"8","author":"Chihara","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2020.102005_bib0006","first-page":"e5543","article-title":"Cranial nerve involvement in patients with MOG antibody-associeted disease","volume":"6","author":"Cobo-Calvo","year":"2019","journal-title":"Neurol. Neuroimmnunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102005_bib0007","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102005_bib0008","doi-asserted-by":"crossref","first-page":"9446","DOI":"10.1073\/pnas.1133443100","article-title":"Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein","volume":"100","author":"Constanze","year":"2003","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"10.1016\/j.msard.2020.102005_bib0101","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1212\/NXI.0000000000000503","article-title":"MOG antibodies in combined central and peripheral demyelination syndromes","volume":"5","author":"Do Campo","year":"2019","journal-title":"Neurol. Neuroimmnunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102005_bib0009","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk,","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2020.102005_bib0010","first-page":"228","article-title":"The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates","volume":"23","author":"Hamid","year":"2017","journal-title":"MSJ"},{"key":"10.1016\/j.msard.2020.102005_bib0011","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","article-title":"Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases","volume":"88","author":"Hyun","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.msard.2020.102005_bib0012","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102005_bib0013","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. part 2: epidemiology, clini- cal presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102005_bib0014","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V97.6.1817","article-title":"Interleukin-6 is a growth factor for nonmalignant human plasmablasts","volume":"97","author":"Jego","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.msard.2020.102005_bib0016","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102005_bib0017","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross- sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.msard.2020.102005_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149411","article-title":"B cell, Th17, and neutrophil related cerebrospinal fluid cytokine\/chemokines are elevated in MOG antibody associated demyelination","volume":"11","author":"Kothur","year":"2016","journal-title":"PLoS. ONE"},{"key":"10.1016\/j.msard.2020.102005_bib0019","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1007\/s00415-011-6086-x","article-title":"Cerebrospinal fluid\/ serum gradient of IGG is associated with disability at acute attacks of neuromyelitis optica","volume":"258","author":"Kim","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102005_bib0020","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2020.102005_bib0022","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IGG marker of opticspinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2020.102005_bib0021","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica :distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102005_bib0023","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102005_bib0024","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clim.2007.11.013","article-title":"Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation","volume":"127","author":"Marie Cardine","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.msard.2020.102005_bib0025","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1212\/NXI.0000000000000619","article-title":"Expanding the MOG phenotype brainstem encephalitis with punctate and curvilinear enhancement","volume":"6","author":"Matesanz","year":"2019","journal-title":"Neurol. Neuroimmnunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102005_bib0026","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.4049\/jimmunol.1301296","article-title":"Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases","volume":"191","author":"Mayer","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2020.102005_bib0027","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2020.102005_bib0028","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol. Neuroimmnunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102005_bib0029","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1212\/NXI.0000000000000538","article-title":"Anti-MOG encephalitis mimicking small vessel CNS vasculitis","volume":"6","author":"Patterson","year":"2019","journal-title":"Neurol. Neuroimmnunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102005_bib0030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cyto.b.20536","article-title":"B cell subsets in healthy children: reference values for evaluation of B cell maturation process in peripheral blood","volume":"78","author":"Piatosa","year":"2010","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.msard.2020.102005_bib0031","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelina- tion","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.msard.2020.102005_bib0032","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-510X(94)90298-4","article-title":"Flow rate of cerebrospinal fluid (CSF) - a concept common to normal blood- CSF barrier function and to dysfunction in neurological diseases","volume":"122","author":"Reiber","year":"1994","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102005_bib0033","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-510X(00)00501-3","article-title":"Cerebrospinal fluid analysis: disease- related data patterns and evaluation programs","volume":"184","author":"Reiber","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102005_bib0035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody- positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2020.102005_bib0036","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","article-title":"Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes","volume":"263","author":"Sep\u00falveda","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102005_bib0037","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.jaci.2015.09.014","article-title":"In-depth characterization of CD24 (high) CD38(high) transitional human B cells reveals different regulatory profiles","volume":"137","author":"Simon","year":"2016","journal-title":"J. Allergy. Clin. Immunolo."},{"key":"10.1016\/j.msard.2020.102005_bib0038","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12974-016-0678-4","article-title":"Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system","volume":"13","author":"Sinmaz","year":"2016","journal-title":"J. neuroinflammation."},{"key":"10.1016\/j.msard.2020.102005_bib0039","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2020.102005_bib0040","doi-asserted-by":"crossref","unstructured":"Takeshita, Y., Obermeier, B., Cotleur, A., et\u00a0al. 2017. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro4. e311.","DOI":"10.1212\/NXI.0000000000000311"},{"key":"10.1016\/j.msard.2020.102005_bib0041","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/00365517709091496","article-title":"Principles of albumin and IGG analyses in neurological disorders. I. establishment of reference values","volume":"37","author":"Tibbling","year":"1977","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.msard.2020.102005_bib0042","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/147323001204000427","article-title":"Blood-brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and cor- relates with clinical disability","volume":"40","author":"Tomizawa","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.msard.2020.102005_bib0044","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG IG-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"Zamvil","year":"2015","journal-title":"Nurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:49:59Z","timestamp":1761900599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482030081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":42,"alternative-id":["S221103482030081X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102005","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood\u2013brain barrier breakdown and peripheral plasmablasts","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102005"}}